111 results about "Malignant Neoplasm Treatment" patented technology

This invention provides a new tumor antigen having an epitope that induces a Th1 cell (a CD4-positive T cell specific to MAGE-A4), and a method ot application thereof.

The invention discloses a mouse monoclonal antibody against a human Siglec-15 protein. The specificity is high, the performance is stable and the titer is high. The invention further relates to application of the monoclonal antibody to preparation of immunohistochemical detection tools for the Siglec-15 protein. According to the mouse monoclonal antibody against the human Siglec-15 protein, an immunohistochemistry method is used for detecting expression of Siglec-15 on the tumor cell surface for selection, the curative effect and the prognosis of therapeutic schedules of malignant tumors. Theinvention further relates to the application of the monoclonal antibody to preparation of antibody drugs for immunotherapy of the malignant tumors. The important application value is achieved. The adopted antibody drugs can be full-length or partial sections (Fab, F(ab)'2 or ScFv) of an Siglec-15 monoclonal antibody or combined use of the Siglec-15 monoclonal antibody and a PD-L1 monoclonal antibody. The malignant tumors mainly include colorectal cancer, endometrial cancer, thyroid cancer, bladder cancer, kidney cancer, lung cancer, liver cancer and the like.

The invention relates to an engineering CD20 targeting NKT cell and a preparation method and application thereof. The cell is an NKT cell modified by chimeric antigen receptor CD20ScFv-CD8-CD137-CD3 sigma, an amino acid sequence of the chimeric antigen receptor is as shown by SEQID NO. 1 in a sequence list. The preparation method comprises the following steps: firstly establishing a chimeric antigen receptor pWPT-CD20ScFv-CD8-CD137-CD3 sigma, infecting the NKT cell, performing in-vitro induction and multiplication culture, and obtaining the engineering CD20 targeting NKT cell. When the engineering CD20 targeting NKT cell is used for treating a CD20 positive malignant tumor at a progressive stage, the survival time of the immune cell in the body of a patient can be obviously prolonged, the capacity of the immune cell for target identifying a tumor antigen is improved, and the killing activity for the tumor cell is improved.

Provided is a method of culturing self-activated lymphocytes applicable to the treatment of malignant tumors. The method raises the percentage's of natural killer (NK) cells of the lymphocytes and evenly activate the NK cells, T cells and natural killer T (NKT) cells, and thus can be used to effectively eliminate various kinds of cancer cells. The method of culturing self- activated lymphocytes involves: extracting lymphocytes from human peripheral blood; performing a first culturing step of culturing the extracted lymphocytes in a culture fluid to which IL-2, L-glutamine and autochthonous plasma are added, in the presence of anti-CD3, anti- CD 16, and anti-CD56 antibodies; and performing a second culturing step of culturing the mixed culture fluid resulting from the first culturing step in the presence of anti-CD3, anti-CD16, and anti-CD56 antibodies after being admixed with a culture fluid to which IL-2, L-glutamine and autochthonous plasma are added.

The invention provides a Chinese medicine preparation for treating malignancy and a preparation method thereof. The preparation method comprises the following steps: firstly, pseudo-ginseng, Rhizoma Zedoariae, fritillariae thunbergii, Atractylodes macrocephala, edible tulip and Polyporus umbellate are dried and crushed into fine powder according to certain weight percent; secondly, Tephroseris kirilowii, Scutellaria barbata, Artemisia capillaries, radix astragali and liquorice with certain weight percent are added with water for decoction, a decoction solution is formed and filtered, and filtrate is decompressed and concentrated into condensed ointment; and thirdly, the fine powder and the condensed ointment are uniformly mixed, dried and crushed into fine powder which is then uniformly mixed and added with adequate water, so as to obtain the Chinese medicine preparation for treating the malignancy. The Chinese medicine preparation has obvious treatment effect on malignancy, particularly has obvious effects on preventing post-operation recurrence and metastasis and lightening the toxic side effect of chemicotherapy, is applicable to various cancer patients without untoward reaction and toxic side effect, relieves the symptoms and prolongs the life of the patients. The preparation method has simple technique, can improve the quality of the medicine and effectively improve the clinic treatment effect of the medicine.

Provided is a medium composition for culturing self- activated lymphocytes applicable to the treatment of malignant tumors, to which anti-CD3, anti-CD16 and anti-CD56 antibodies are added along with interleukin2 (IL-2) to evenly activate natural killer (NK) cells, T cells and natural killer T (NKT) cells, and thus the medium composition can be used to culture im- munocytes that can effectively treat various kinds of malignant tumors. The medium composition includes a cell culture medium and additives added to the cell culture medium, wherein the additives include interleukin2 (IL-2), anti-CD3 antibodies, anti-CD16 antibodies, and anti-CD56 antibodies.

This invention provides a new tumor antigen having an epitope that induces a Th1 cell (a CD4-positive T cell specific to MAGE-A4), and a method of application thereof.Specifically, this invention provides a polypeptide that includes an amino acid sequence having the following characteristic a), b), c), d), e) or f) and has a cytokine-producing activity in a Th cell specific to MAGE-A4:a) An amino acid sequence represented by SEQ ID No: 1 or No: 2;b) An amino acid sequence, wherein one to several tens of any amino acids are added to N terminus and / or C terminus of an amino acid sequence represented by SEQ ID No: 1 or No: 2;c) An amino acid sequence, wherein one to five amino acids from N terminus and / or C terminus of an amino acid sequence represented by SEQ ID No: 1 or No: 2 are deleted;d) An amino acid sequence, wherein one to several amino acid residues of an amino acid sequence represented by SEQ ID No: 1 or No: 2 are substituted and / or deleted;e) An amino acid sequence, wherein one to several tens of any amino acids are added to N terminus and / or C terminus of an amino acid sequence, wherein one to several amino acid residues of an amino acid sequence represented by SEQ ID No: 1 or No: 2 are substituted and / or deleted; andf) An amino acid sequence, wherein one to several amino acid residues are substituted in an amino acid sequence, wherein one to five amino acids from N terminus and / or C terminus of an amino acid sequence represented by SEQ ID No: 1 or No: 2 are deleted.

Disclosed is a medium composition for culturing self-activated lymphocytes, which contains anti-CD3 antibody and anti-CD16 antibody in addition to interleukin 2 (IL-2), interleukin 12 (IL-12) and interleukin 18 (IL-18) in a medium, and thus can efficiently proliferate and activate NK cells, T cells and NKT cells and, at the same time, can significantly increase the ratio of NK cells in lymphocytes so as to provide immunocytes having excellent effects on the treatment of various kinds of malignant tumors, and a method for culturing self-activated lymphocytes using the medium composition.

Antineoplastic dendritic polymer conjugates which are useful drug delivery systems for carrying antineoplastic agents to malignant tumors are prepared. The antineoplastic agent is encapsulated within the dendritic polymer using an ionic charge shunt mechanism, whereby, the antineoplastic agent interacts with the anionic functional groups on the surface of the dendritic polymer allowing the antineoplastic agent to be uptaken by the dendritic polymer through an association with the functional groups of the interior of the dendritic polymer. The antineoplastic dendritic polymer conjugates may be administered intravenously, orally, parentally, subcutaneously, intraarterially or topically to an animal having a malignant tumor in an amount which is effective to inhibit growth of the malignant tumor. The antineoplastic dendritic polymer conjugates exhibit high drug efficiency, high drug carrying capacity, good water solubility, good stability on storage, and reduced toxicity.

The invention relates to an anti-tumor dendric polypeptide macromolecule medicine vector system and application thereof in pharmacy. The dendric polypeptide macromolecule can be prepared by the solid phase, liquid phase or solid-liquid combination method of single or different natural amino acids, and can be used for preparing a vector release system which is loaded with malignant tumor resisting treatment medicines. The dendric polypeptide macromolecule medicine vector system is a covalent bond vector medicine system in which anti-tumor activity micromolecule medicines are sealed in dendric polypeptide macromolecule polymers, or the anti-tumor activity micromolecules are combined with functional groups on the surfaces of the anti-tumor dendric polypeptide macromolecules. The dendric polypeptide macromolecule medicine vector system can correspondingly inhibit growth of the malignant tumor and is applied to a patient suffered from the malignant tumor in the modes of venous, oral-taking, endermic and arterial administration or local administration. The anti-tumor dendric polypeptide macromolecule medicine vector system has the advantages of high targeting property, high medicine carrying capability, good waster solubility and stability and lower toxicity.

The invention provides a preparation method for a probiotics system. The stable exogenous probiotics system can be obtained by using the method. After being taken, the probiotics system can form a stable microenvironment in a host, can take the effect of changing composition of intestinal microorganisms and finally exerts a positive role during treatment of a malignant tumor.